Literature DB >> 23857589

A conceptual and methodological framework for investigating etiologic heterogeneity.

Colin B Begg1, Emily C Zabor, Jonine L Bernstein, Leslie Bernstein, Michael F Press, Venkatraman E Seshan.   

Abstract

Cancer has traditionally been studied using the disease site of origin as the organizing framework. However, recent advances in molecular genetics have begun to challenge this taxonomy, as detailed molecular profiling of tumors has led to discoveries of subsets of tumors that have profiles that possess distinct clinical and biological characteristics. This is increasingly leading to research that seeks to investigate whether these subtypes of tumors have distinct etiologies. However, research in this field has been opportunistic and anecdotal, typically involving the comparison of distributions of individual risk factors between tumors classified on the basis of candidate tumor characteristics. The purpose of this article is to place this area of investigation within a more general conceptual and analytic framework, with a view to providing more efficient and practical strategies for designing and analyzing epidemiologic studies to investigate etiologic heterogeneity. We propose a formal definition of etiologic heterogeneity and show how classifications of tumor subtypes with larger etiologic heterogeneities inevitably possess greater disease risk predictability overall. We outline analytic strategies for estimating the degree of etiologic heterogeneity among a set of subtypes and for choosing subtypes that optimize the heterogeneity, and we discuss technical challenges that require further methodologic research. We illustrate the ideas by using a pooled case-control study of breast cancer classified by expression patterns of genes known to define distinct tumor subtypes.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer epidemiology; clustering; etiologic heterogeneity

Mesh:

Substances:

Year:  2013        PMID: 23857589      PMCID: PMC4104361          DOI: 10.1002/sim.5902

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  34 in total

1.  Comparing ROC curves derived from regression models.

Authors:  Venkatraman E Seshan; Mithat Gönen; Colin B Begg
Journal:  Stat Med       Date:  2012-10-03       Impact factor: 2.373

2.  Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.

Authors:  M C Stern; D M Umbach; M C Yu; S J London; Z Q Zhang; J A Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-06       Impact factor: 4.254

Review 3.  Statistical analysis of case-control studies.

Authors:  W D Thompson
Journal:  Epidemiol Rev       Date:  1994       Impact factor: 6.222

4.  The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.

Authors:  Polly A Marchbanks; Jill A Mcdonald; Hoyt G Wilson; Nancy M Burnett; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Brian L Strom; Sandra A Norman; Linda K Weiss; Jonathan M Liff; Phyllis A Wingo; Ronald T Burkman; Suzanne G Folger; Jesse A Berlin; Dennis M Deapen; Giske Ursin; Ralph J Coates; Michael S Simon; Michael F Press; Robert Spirtas
Journal:  Ann Epidemiol       Date:  2002-05       Impact factor: 3.797

5.  The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).

Authors:  Robert E Tarone; Kenneth C Chu
Journal:  Cancer Causes Control       Date:  2002-02       Impact factor: 2.506

6.  Oral-contraceptive use and the risk of breast cancer.

Authors: 
Journal:  N Engl J Med       Date:  1986-08-14       Impact factor: 91.245

7.  Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States).

Authors:  H Furberg; R C Millikan; J Geradts; M D Gammon; L G Dressler; C B Ambrosone; B Newman
Journal:  Cancer Causes Control       Date:  2003-09       Impact factor: 2.506

Review 8.  Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.

Authors:  Michelle D Althuis; Jennifer H Fergenbaum; Montserrat Garcia-Closas; Louise A Brinton; M Patricia Madigan; Mark E Sherman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-10       Impact factor: 4.254

9.  The evaluation of the data collection process for a multicenter, population-based, case-control design.

Authors:  P A Wingo; H W Ory; P M Layde; N C Lee
Journal:  Am J Epidemiol       Date:  1988-07       Impact factor: 4.897

10.  Semi-supervised methods to predict patient survival from gene expression data.

Authors:  Eric Bair; Robert Tibshirani
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

View more
  21 in total

1.  The competing risks Cox model with auxiliary case covariates under weaker missing-at-random cause of failure.

Authors:  Daniel Nevo; Reiko Nishihara; Shuji Ogino; Molin Wang
Journal:  Lifetime Data Anal       Date:  2017-08-04       Impact factor: 1.588

Review 2.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

Review 3.  Proceedings of the third international molecular pathological epidemiology (MPE) meeting.

Authors:  Peter T Campbell; Timothy R Rebbeck; Reiko Nishihara; Andrew H Beck; Colin B Begg; Alexei A Bogdanov; Yin Cao; Helen G Coleman; Gordon J Freeman; Yujing J Heng; Curtis Huttenhower; Rafael A Irizarry; N Sertac Kip; Franziska Michor; Daniel Nevo; Ulrike Peters; Amanda I Phipps; Elizabeth M Poole; Zhi Rong Qian; John Quackenbush; Harlan Robins; Peter K Rogan; Martha L Slattery; Stephanie A Smith-Warner; Mingyang Song; Tyler J VanderWeele; Daniel Xia; Emily C Zabor; Xuehong Zhang; Molin Wang; Shuji Ogino
Journal:  Cancer Causes Control       Date:  2017-01-17       Impact factor: 2.506

Review 4.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

5.  Metallic air pollutants and breast cancer heterogeneity.

Authors:  Jacob K Kresovich; Serap Erdal; Hua Yun Chen; Peter H Gann; Maria Argos; Garth H Rauscher
Journal:  Environ Res       Date:  2019-08-08       Impact factor: 6.498

6.  Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study.

Authors:  Halei C Benefield; Emily C Zabor; Yue Shan; Emma H Allott; Colin B Begg; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-08       Impact factor: 4.254

7.  A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers.

Authors:  Molin Wang; Aya Kuchiba; Shuji Ogino
Journal:  Am J Epidemiol       Date:  2015-06-26       Impact factor: 4.897

8.  Utility of inverse probability weighting in molecular pathological epidemiology.

Authors:  Li Liu; Daniel Nevo; Reiko Nishihara; Yin Cao; Mingyang Song; Tyler S Twombly; Andrew T Chan; Edward L Giovannucci; Tyler J VanderWeele; Molin Wang; Shuji Ogino
Journal:  Eur J Epidemiol       Date:  2017-12-20       Impact factor: 8.082

9.  Statistical methods for studying disease subtype heterogeneity.

Authors:  Molin Wang; Donna Spiegelman; Aya Kuchiba; Paul Lochhead; Sehee Kim; Andrew T Chan; Elizabeth M Poole; Rulla Tamimi; Shelley S Tworoger; Edward Giovannucci; Bernard Rosner; Shuji Ogino
Journal:  Stat Med       Date:  2015-12-01       Impact factor: 2.373

Review 10.  Integration of molecular pathology, epidemiology and social science for global precision medicine.

Authors:  Akihiro Nishi; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Andy S Tan; Ichiro Kawachi; Shuji Ogino
Journal:  Expert Rev Mol Diagn       Date:  2015-12-04       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.